Chronic low-grade inflammation in polyendocrine metabolic ovarian syndrome: Metabolic dysregulation and the emerging link with metabolic dysfunction associated steatotic liver disease
Letters in Drug Design & Discovery · 2026-09 · 23 (9) · 100606
DOI: 10.1016/j.lddd.2026.100606 ↗Kurz gefasst
Fachartikel in der Zeitschrift Letters in Drug Design & Discovery, 2026-09. Verfasst von K. Meghana und 4 weiteren Autor:innen. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
PMOS is a complex condition of the endocrine system involving reproductive and metabolic disturbances such as insulin resistance, dyslipidemia, and chronic inflammation. The role of inflammation in metabolic dysfunction in PMOS is discussed in this narrative review with a focus on a possible association with metabolic dysfunction associated steatotic liver disease (MASLD). It is supported by evidence from clinical, observational, and mechanistic studies that inflammatory biomarkers, such as CRP, IL-6, and TNF-α, are found to be elevated in women with PMOS and may impair insulin action by promoting inhibitory serine phosphorylation of IRS-1 and disrupting the subsequent PI3K/AKT signaling pathway. This insulin resistance causes compensatory hyperinsulinemia, which leads to increased synthesis of ovarian androgens along with decreased synthesis of sex hormone binding globulin in the liver. Concurrently, insulin resistance, dyslipidemia, inflammation, androgens, and gut-liver-ovary interactions may be involved in hepatic fat deposition and MASLD, even in lean PMOS women. In addition, the review outlines novel therapeutic approaches which could address this immune-metabolic cross-talk, such as glucagon-like peptide-1 receptor agonists, GLP-1/GIP dual agonists, sodium-glucose cotransporter-2 inhibitors, and therapies targeting the NLRP3 inflammasome. Nonetheless, the role of certain emerging therapeutic targets is still poorly investigated and is mainly pre-clinical, while causal relationship between inflammation and hepatic consequences has not yet been proven. The combination of inflammatory, metabolic and hepatic pathways could advance knowledge on the pathogenesis of PMOS, and lead to the development of tailored risk stratification and treatment in the future.
Zitieren
APA
Meghana, K., Devi, C. A., Poongavanam, S. S., Kirubakaran, D., & Manikandan, C. (2026). Chronic low-grade inflammation in polyendocrine metabolic ovarian syndrome: Metabolic dysregulation and the emerging link with metabolic dysfunction associated steatotic liver disease. Letters in Drug Design & Discovery, 23(9), 100606. https://doi.org/10.1016/j.lddd.2026.100606
Vancouver
Meghana K, Devi CA, Poongavanam SS, Kirubakaran D, Manikandan C. Chronic low-grade inflammation in polyendocrine metabolic ovarian syndrome: Metabolic dysregulation and the emerging link with metabolic dysfunction associated steatotic liver disease. Letters in Drug Design & Discovery. 2026;23(9):100606. doi:10.1016/j.lddd.2026.100606
BibTeX
@article{Meghana2026,
author = {Meghana, K. and Devi, C. Anchana and Poongavanam, Senthamil Selvi and Kirubakaran, Dharmalingam and Manikandan, Chitrarasu},
title = {Chronic low-grade inflammation in polyendocrine metabolic ovarian syndrome: Metabolic dysregulation and the emerging link with metabolic dysfunction associated steatotic liver disease},
journal = {Letters in Drug Design & Discovery},
year = {2026},
volume = {23},
number = {9},
pages = {100606},
doi = {10.1016/j.lddd.2026.100606}
}
EUVIMED